Singlomics Biopharmaceuticals is an innovative biopharmaceutical company committed to the discovery and development of antibody drugs for infectious diseases and cancers using single-cell sequencing technology. It has established a state of the art single-cell high-throughput drug screening and development platform. As a novel drug development strategy, this technology has been used to achieve rapid discovery and development of antibody drugs. The advantages of this technology include utilizing immune cells with well-defined biological functions as target cell population, and adopting a high-content and higher-throughput process to achieve higher efficiency than conventional antibody discovery technologies. It can greatly shorten the time and reduce the failure rate of antibody discovery. Singlomics has completed series B round of financing from investors in the medical and healthcare field in China, to enhancing the pipelines to treat infectious diseases and cancer, through strengthening in-house R&D capabilities for novel antibody drugs. Our goal is to develop high quality and affordable therapeutics for the people in need.